



See your health before symptoms begin.

---

Cuffless wearable device for continuous BP & glucose monitoring

# 800 million

Diabetes



▶ Cuff-based monitoring

# 1.2 billion

Hypertension



▶ Painful finger pricks



▶ No sleep data

# Problem

---

**32%**

*Misdiagnosed*

**0%**

*Nocturnal Events Captured*

**10M+**

*Deaths per Year*

**5**

*Daily Measurements (Finger Pricks)*

**50%**

*Data Capture*

# Solution: HakuCare

---



Non-invasive

24/7 monitoring

No cuff. No needle.


**Health monitoring. Simplified.**

**Protected by 2 filed patents**

# Advanced Pressure-Sensing Technology


## Optical-based wearables (PPG)

Light-sensitive, unstable



## HakuCare Technology


Captures full pulse waveform



**More data. Higher stability. Greater accuracy.**

# How HakuCare Works

---



# What Changes With HakuCare

---

↓ 20%

*Misdiagnosed*

↓ 100%

*Nocturnal Events Captured*

↓ 1M

*Lives saved/yr*

↓ 2


*Daily Measurements (Finger Pricks)*

↓ 100%

*Data Capture*

# Market Size


---



## Target market across US, Japan, and China

- **TAM:** Hypertension & diabetes patients
- **SAM :** Addressable patient population (in US, Japan, and China)
- **Initial Focus (SOM):**  
Patients dissatisfied with current BP & glucose monitoring
- **Pricing model:** \$300 per device

## 90% Buy-in



Diabetes patient



Hypertension patient

- Customers frustrated with current blood sugar and blood pressure monitoring options.
- Eager to buy a non-invasive wearable solution.
- Broad appeal across US, Japan, and China.

# Go to Market

---

## B2C

- ✓ Direct online launch
- ✓ Subscription-based data service
- ✓ Partnerships with pharmacies
- ✓ Insurance collaboration (future phase)

## B2B

- ✓ Clinics
- ✓ Hospitals
- ✓ Doctors offices
- ✓ Channel partners

# Business Model

---

Per device

\$300

Subscription

\$200/month

# Roadmap



## IP & Validation

Q1 2026 – Q3 2027

Patent filings completed

Clinical validation studies

Prototype optimization



## Company Launch

Q4 2027 – Q3 2028

Company incorporation

Pilot programs

Initial revenue generation



## Regulatory Approval

Q4 2028 – 2029

PMDA (Japan)

FDA (US)

CE Mark (EU)



## Global Scale

2029+

Manufacturing scale-up

International distribution

Strategic partnerships

# Team

---



***Minyu LI***

***Co-founder & CEO***

***Ph.D. Candidate Infomatics  
MA Infomatics  
BS Mechanical Engineering***



***Hedong ZHANG***

***Co-founder & CTO***

***Ph.D. Engineering  
MA Engineering  
BS Engineering***



# \$500,000

---

## Milestones

- 5 LOI
- 3 Pilots
- MRR: \$20,000